Table 3.
Distribution of patient-level tumor response data from published clinical studies in BRAF V600E-CRC
% Change from baseline | CETUX + VEMU% (N) | BRAFi + MEKi% (N) | EGFRi + BRAFi + MEKi% (N) |
---|---|---|---|
100+ | 0 | 0 | 0 |
50:100 | 3.8 (1) | 2.6 (1) | 2.9 (1) |
20:50 | 11.5 (3) | 10.5 (4) | 0 |
0:20 | 30.8 (8) | 26.3 (10) | 11.4 (4) |
−30:0 | 30.8 (8) | 47.4 (18) | 48.6 (16) |
−50:−30 | 7.7 (2) | 10.5 (4) | 20.0 (8) |
−100:−30 | 15.4 (4) | 2.6 (1) | 17.1 (6) |
Calculated ORR | 23.1 (6/26) | 13.1 (5/38) | 37.1 (13/35) |
Reported ORR | 4 (1/27) | 12 (5/43) | 26 (9/35) |